Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $85.81 USD
Change Today +0.42 / 0.49%
Volume 1.4M
ENDP On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Open
$85.09
Previous Close
$85.39
Day High
$85.98
Day Low
$84.05
52 Week High
04/16/15 - $96.58
52 Week Low
10/15/14 - $57.14
Market Cap
17.9B
Average Volume 10 Days
1.6M
EPS TTM
$2.88
Shares Outstanding
208.2M
EX-Date
--
P/E TM
29.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENDO INTERNATIONAL PLC (ENDP)

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, including Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain management, urology, CNS disorders, immunosuppression, oncology, women’s health, hypertension, generic lidocaine patch, and other markets. The Devices segment provides various medical devices comprising AMS 800 artificial urinary sphincters, AMS 700 MS series, Monarc subfascial hammock products, Elevate anterior and posterior pelvic floor repair systems, and GreenLight XPS laser systems in the areas of men’s and women’s pelvic health. The International Pharmaceuticals segment offers Dexedrine, Tridural, Metadol, Trandate, Pennsaid, and Plan B products in therapeutic areas, including attention deficit hyperactivity disorder, pain, urology, and allergy. It sells its branded pharmaceuticals and generics directly to large pharmacy chains; and through wholesale drug distributors to pharmacies, hospitals, governmental agencies, and physicians. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

5,062 Employees
Last Reported Date: 03/2/15
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $835.8K
President of American Medical Systems, Inc
Total Annual Compensation: $567.8K
Special Advisor to the Chief Executive Office...
Total Annual Compensation: $660.3K
Consultant
Total Annual Compensation: $576.2K
Compensation as of Fiscal Year 2014.

endo international plc (ENDP) Key Developments

Endo International plc Proposes Private Offering of Senior Notes

Endo International plc announced that Endo Limited, Endo Finance LLC and Endo Finco Inc. intend to offer senior notes, subject to market and customary conditions. The notes will be unsecured, unsubordinated obligations of Endo Limited, Endo Finance LLC and Endo Finco Inc. and will be guaranteed by certain of Endo Limited's direct and indirect subsidiaries. Endo intends to use the net proceeds from the proposed offering, together with the proceeds of new senior secured credit facilities and cash on hand, to fund the purchase price of the previously announced acquisition of Par Pharmaceutical Holdings Inc. (Par), as well as for repayments of indebtedness of Par and certain transaction expenses. Endo intends to use any remaining proceeds for general corporate purposes, including acquisitions and debt repayments. The notes and the related guarantees have not been and will not be registered under the Securities Act of 1933, as amended, or any applicable state or foreign securities laws, and will be offered only to qualified institutional buyers in reliance on Rule 144A, and outside the United States in compliance with Regulation S under the Securities Act. Unless so registered, the notes and the related guarantees may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws.

Endo Mulls Acquisitions

Endo International plc (NasdaqGS:ENDP) is seeking acquisitions. Endo announced that Endo Limited, Endo Finance LLC and Endo Finco Inc., its wholly-owned subsidiaries, intend to offer senior notes, subject to market and customary conditions. Endo intends to use the net proceeds from the proposed offering, together with the proceeds of new senior secured credit facilities and cash on hand, to fund the purchase price of the previously announced acquisition of Par Pharmaceutical Holdings, Inc. ("Par"), as well as for repayments of indebtedness of Par and certain transaction expenses. Endo intends to use any remaining proceeds for general corporate purposes, including acquisitions and debt repayments.

Endo International Mulls Acquisitions

Endo International plc (NasdaqGS:ENDP) is seeking acquisitions. Endo International plc has commenced an underwritten public offering of $1.75 billion of ordinary shares. Endo International will also grant to the underwriters of the offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase an additional $262.5 million of ordinary shares at the public offering price, less the underwriting discounts and commissions. Endo International expects to use the proceed from offering for purposes including The Company intends to use any remaining proceeds for general corporate purposes, including acquisitions and debt repayments.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $85.81 USD +0.42

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.141.60 CHF -2.30
CR Bard Inc $190.14 USD +2.39
Edwards Lifesciences Corp $152.72 USD -2.38
Mallinckrodt PLC $123.08 USD -0.74
UCB SA €69.50 EUR -1.07
View Industry Companies
 

Industry Analysis

ENDP

Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.